975 related articles for article (PubMed ID: 26040768)
21. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
23. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt.
Xu Z; Mei J; Tan Y
Int J Oncol; 2017 Jan; 50(1):93-100. PubMed ID: 27878245
[TBL] [Abstract][Full Text] [Related]
24. Overcoming Basal Autophagy, Kangai Injection Enhances Cisplatin Cytotoxicity by Regulating FOXO3a-Dependent Autophagic Cell Death and Apoptosis in Human Lung Adenocarcinoma A549/DDP Cells.
Zhou H; Pan P; Zhao Q; Liu W; Sun Y; Wang J; Liu C; Wang C
Biomed Res Int; 2022; 2022():6022981. PubMed ID: 36093402
[TBL] [Abstract][Full Text] [Related]
25. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
28. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
29. 7-O-geranylquercetin-induced autophagy contributes to apoptosis via ROS generation in human non-small cell lung cancer cells.
Wang EX; Zou BY; Shi L; Du LY; Zhu YY; Jiang YM; Ma XD; Kang XH; Wang CY; Zhen YH; Sun LD
Life Sci; 2017 Jul; 180():102-113. PubMed ID: 28495516
[TBL] [Abstract][Full Text] [Related]
30. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
31. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
32. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
33. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
34. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
35. DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p.
Li C; Chen L; Song W; Peng B; Zhu J; Fang L
Acta Histochem; 2021 Oct; 123(7):151788. PubMed ID: 34543777
[TBL] [Abstract][Full Text] [Related]
36. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
[TBL] [Abstract][Full Text] [Related]
37. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
38. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
40. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
